1. Home
  2. BOLT vs UTSI Comparison

BOLT vs UTSI Comparison

Compare BOLT & UTSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BOLT
  • UTSI
  • Stock Information
  • Founded
  • BOLT 2015
  • UTSI 1991
  • Country
  • BOLT United States
  • UTSI China
  • Employees
  • BOLT N/A
  • UTSI N/A
  • Industry
  • BOLT Biotechnology: Pharmaceutical Preparations
  • UTSI Telecommunications Equipment
  • Sector
  • BOLT Health Care
  • UTSI Telecommunications
  • Exchange
  • BOLT Nasdaq
  • UTSI Nasdaq
  • Market Cap
  • BOLT 25.3M
  • UTSI 25.4M
  • IPO Year
  • BOLT 2021
  • UTSI 2000
  • Fundamental
  • Price
  • BOLT $0.52
  • UTSI $2.45
  • Analyst Decision
  • BOLT Hold
  • UTSI
  • Analyst Count
  • BOLT 5
  • UTSI 0
  • Target Price
  • BOLT $1.25
  • UTSI N/A
  • AVG Volume (30 Days)
  • BOLT 168.8K
  • UTSI 8.3K
  • Earning Date
  • BOLT 11-12-2024
  • UTSI 09-05-2024
  • Dividend Yield
  • BOLT N/A
  • UTSI N/A
  • EPS Growth
  • BOLT N/A
  • UTSI N/A
  • EPS
  • BOLT N/A
  • UTSI N/A
  • Revenue
  • BOLT $9,779,000.00
  • UTSI $14,958,000.00
  • Revenue This Year
  • BOLT $9.87
  • UTSI N/A
  • Revenue Next Year
  • BOLT N/A
  • UTSI N/A
  • P/E Ratio
  • BOLT N/A
  • UTSI N/A
  • Revenue Growth
  • BOLT 35.86
  • UTSI 14.41
  • 52 Week Low
  • BOLT $0.50
  • UTSI $2.20
  • 52 Week High
  • BOLT $1.56
  • UTSI $3.54
  • Technical
  • Relative Strength Index (RSI)
  • BOLT 38.20
  • UTSI 36.82
  • Support Level
  • BOLT $0.50
  • UTSI $2.57
  • Resistance Level
  • BOLT $0.59
  • UTSI $2.80
  • Average True Range (ATR)
  • BOLT 0.03
  • UTSI 0.15
  • MACD
  • BOLT -0.00
  • UTSI -0.03
  • Stochastic Oscillator
  • BOLT 24.49
  • UTSI 0.00

About BOLT Bolt Biotherapeutics Inc.

Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on our deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.

About UTSI UTStarcom Holdings Corp.

UTStarcom Holdings Corp operates as a telecom infrastructure provider. It develops technology for bandwidth from cloud-based services, mobile, streaming, and other applications. The range of solutions is designed to expand and modernize telecommunications networks through smooth network system integration, lower operating costs, and increased broadband access. The business activity of the firm is operated through the Equipment and Service segment. The Equipment segment is focused on equipment sales, including network infrastructure and application products, and the Service segment is engaged in providing services and support of equipment products and also the new operational support. The company operates in China, India, Japan, Taiwan and other countries.

Share on Social Networks: